UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 10,656	$ 7,386
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	483	495
Amortization	4,996	4,875
Provision for (recovery of) losses on accounts receivable	20	(4)
Amortization of Right of Use Assets	32	29
(Gain) loss on disposal of assets	0	1
Deferred income taxes	(160)	(20)
Stock-based compensation expense	123	121
Tax benefit attributable to exercise of stock options	11	7
Changes in operating assets and liabilities:
Accounts receivable and other receivables	(802)	442
Inventories	(161)	757
Prepaid expenses and other current assets	(35)	58
Accounts payable	242	(439)
Accrued expenses	811	651
Total adjustments	5,560	6,973
Net cash provided by operating activities	16,216	14,359
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment	(299)	(806)
Net cash used in investing activities	(299)	(806)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options	281	282
Common stock purchased and retired	0	(6,977)
Payment of dividends	(3,116)	(3,097)
Net cash used in financing activities	(2,835)	(9,792)
Effect of exchange rate changes on cash	(351)	(254)
Net increase in cash and cash equivalents	12,731	3,507
Cash at beginning of period	51,590	42,787
Cash at end of period	64,321	46,294
Cash paid during the period for income taxes	3,094	2,153
Cash paid during the period for interest	$ 0	$ 0